Bydureon approval buoys Amylin

Amylin Pharmaceuticals Inc. (NASDAQ:AMLN) gained $2.12 (17%) to $14.26 on Monday after FDA approved once-weekly Bydureon exenatide on Friday to treat Type II diabetes. Amylin said the drug will be ava...